FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Kymera Therapeutics, Inc. is among the ...

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and ...

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Healio

FDA grants fast track designation to KT-621 for moderate to severe eosinophilic asthma

The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according ...
Pharmabiz

Thryv Therapeutics begins patient enrollment in Wave II study for Long QT Syndrome; receives US FDA fast track designation for THRV-1268

Thryv Therapeutics begins patient enrollment in Wave II study for Long QT Syndrome; receives US FDA fast track designation for THRV-1268: San Francisco Saturday, April 25, 2026, 1 ...

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant ...
Targeted Oncology

FDA Grants Fast Track Designation to BBO-11818 in KRAS-Mutant PDAC

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
TMCnet

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be ...
WFXG

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis

FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a ...

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to ...